Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
recombinant PRAME protein plus AS15 adjuvant
- Development stage
- Unknown
- Lead developer
- GSK
- Modality
- Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Recombinant PRAME protein plus AS15 adjuvant is an investigational cancer immunotherapy composed of a recombinant form of the tumor antigen PRAME (Preferentially Expressed Antigen in Melanoma) combined with the proprietary AS15 immunostimulant adjuvant system. This combination is designed to stimulate the immune system to recognize and attack tumor cells expressing PRAME. The therapy works by inducing strong PRAME-specific antibody and T-cell responses, particularly CD4+ T cells, which may help control or prevent recurrence of cancers that express this antigen. The drug is being developed primarily for use as an adjuvant treatment in resected non-small cell lung cancer (NSCLC) and melanoma. It is currently in phase I/II clinical development for these indications[1][2][4][5]. The developer is GSK.
- Other names
- PRAME cancer immunotherapeuticantigen-specific cancer immunotherapeutic (ASCI)recPRAME + AS15 Antigen-Specific Cancer Immunotherapeutic
02
Targets
PRAME (Preferentially expressed antigen in melanoma)
Beyond the preview
Go deeper on recombinant PRAME protein plus AS15 adjuvant.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on recombinant PRAME protein plus AS15 adjuvant.